Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants-Reference-Cited by-同舟云学术

Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants

Published:2024-01-12 Issue: Volume:12 Page:
ISSN:2296-2360
Container-title:Frontiers in Pediatrics
language:
Short-container-title:Front. Pediatr.

Author:

Paes Bosco,Lanari Marcello,Rodgers-Gray Barry,Fullarton John,Carbonell-Estrany Xavier

Publisher

Frontiers Media SA

Reference41 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis;Li;Lancet,2022

2. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease;Figueras-Aloy;Infect Dis Ther,2016

3. Burden of respiratory syncytial virus hospitalisation among infants born at 32–35 weeks’ gestational age in the northern hemisphere: pooled analysis of seven studies;Lanari;Epidemiol Infect,2020

4. Universal infant immunisation against respiratory syncytial virus and European inequalities: the pandemics lesson has not been learnt;De Luca;Lancet Reg Health Eur,2023

5. Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants;Blanken;Pediatr Pulmonol,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maternal Risk Factors for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Otherwise Healthy Preterm and Term Infants: A Systematic Review and Meta-analysis;Pediatric Infectious Disease Journal;2024-05-15